Capricor Therapeutics (CAPR) Short-term Investments (2012 - 2026)

Capricor Therapeutics' Short-term Investments history runs 13 years deep, the most recent figure standing at $173.2 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 49.32% year-over-year to $173.2 million; the TTM figure through Mar 2026 stood at $173.2 million (up 49.32% YoY), while the FY2025 annual figure was $30.3 million, down 78.41% from the prior year.
• Short-term Investments was $173.2 million for Q1 2026 at Capricor Therapeutics, up from $30.3 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $173.2 million in Q1 2026 to a low of $16.7 million in Q3 2024.
• Historically, Short-term Investments has averaged $57.5 million across 5 years, with a median of $34.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Short-term Investments surged 465.6% in 2024, then slumped 78.41% in 2025.
• A 5-year view of Short-term Investments shows it stood at $31.8 million in 2022, then declined by 22.08% to $24.8 million in 2023, then soared by 465.6% to $140.2 million in 2024, then plunged by 78.41% to $30.3 million in 2025, then surged by 471.93% to $173.2 million in 2026.
• The last three Short-term Investments figures came in at $173.2 million (Q1 2026), $30.3 million (Q4 2025), and $79.1 million (Q3 2025), per Business Quant data.